Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle

被引：0
|
作者：
Devidas Menon
Tania Stafinski
Andrea Dunn
Durhane Wong-Rieger
机构：
[1] University of Alberta,Health Technology and Policy Unit, School of Public Health
[2] Canadian Organization for Rare Disorders,undefined
来源：
The Patient - Patient-Centered Outcomes Research | 2015年 / 8卷
关键词：
Rare Disease; Orphan Drug; Policy Framework; Patient Input; Decision Uncertainty;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：103 / 117
页数：14
相关论文
共 28 条
  • [1] Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
    Menon, Devidas
    Stafinski, Tania
    Dunn, Andrea
    Wong-Rieger, Durhane
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (01): : 103 - 117
  • [2] ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND
    Achour, L.
    Hanna, E.
    Borrisov, B.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S446 - S446
  • [3] TITLE: ACCESS TO ORPHAN AND ULTRA-ORPHAN DRUGS IN CHINA
    Gambari, J.
    Yang, M.
    Chowdhury, C. A.
    Duttagupta, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A826 - A826
  • [4] International differences in patient access to ultra-orphan drugs
    Kanters, Tim A.
    Redekop, W. Ken
    Hakkaart, Leona
    [J]. HEALTH POLICY AND TECHNOLOGY, 2018, 7 (01) : 57 - 64
  • [5] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [6] PATIENT VOICE IN SMC TECHNOLOGY APPRAISALS FOR ORPHAN AND ULTRA-ORPHAN DISEASES
    Gupta, A.
    Jindal, S.
    Mahajan, K.
    Sharma, A.
    Saharia, P.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S486 - S486
  • [7] Ultra-orphan drugs: can we afford the price
    Menon, Devidas
    Stafinski, Tania
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (08): : 611 - 612
  • [8] MARKET ACCESS AND PRICING ANALYSIS OF ULTRA-ORPHAN DRUGS
    Malacan, J.
    Gabriel, S.
    Dinet, J.
    Forget, S.
    Borget, I
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
  • [9] HOW DOES THE SCOTTISH MEDICINES CONSORTIUM ASSESS THE VALUE OF ORPHAN AND ULTRA-ORPHAN DRUGS?
    Rothwell, B.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A568 - A568
  • [10] Involving Patients in Reducing Decision Uncertainties Around Orphan and Ultra-Orphan Drugs: A Rare Opportunity?
    Menon, Devidas
    Stafinski, Tania
    Dunn, Andrea
    Short, Hilary
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (01): : 29 - 39
123